Jaguar Health, Inc. (NASDAQ:JAGX) | WebDisclosure

Switch to English

10359	Sociétés
215636	Mots-clés
145426	Articles
114219	Communiqués

Accueil
Sociétés
Jaguar Health, Inc.

COMMUNIQUÉ DE PRESSE

publié le 13/04/2026 à 14:30, il y a 23 jours 17 heures

Artificial Intelligence (AI) Platforms Could Enhance Jaguar Health's Development and Anticipated Commercialization of Crofelemer for Rare Disease Intestinal Failure (IF) Programs
Jaguar Health plans to utilize AI platforms to enhance the development and commercialization of crofelemer for intestinal failure treatment, targeting ultrarare pediatric disorder MVID

Crofelemer Jaguar Health MVID AI Platforms Intestinal Failure
BRÈVE

publiée le 10/04/2026 à 02:20, il y a 27 jours 5 heures

Jaguar Health Schedules Investor Webcast on Q4 2025 Financials

Financial Updates Forward-looking Statements Investor Webcast Jaguar Health Gastrointestinal Treatments
BRÈVE

publiée le 10/04/2026 à 02:20, il y a 27 jours 5 heures

Jaguar Health programme une webdiffusion pour les investisseurs sur ses résultats financiers du quatrième trimestre 2025.

Jaguar Health Déclarations Prospectives Actualités Financières Webinaire Pour Les Investisseurs Traitements Gastro-intestinaux
COMMUNIQUÉ DE PRESSE

publié le 10/04/2026 à 02:15, il y a 27 jours 6 heures

Reminder: Jaguar Health to Host Investor Webcast at 8:30 am Eastern on Friday, April 10, 2026 Regarding Q4 2025 Financials and Company Updates
Jaguar Health, Inc. announces participation details for upcoming webcast on April 10, 2026. Learn about their novel prescription drugs derived from plants for GI diseases

Forward-looking Statements Webcast Jaguar Health GI Diseases Prescription Drugs
BRÈVE

publiée le 08/04/2026 à 14:35, il y a 28 jours 17 heures

Jaguar Health achève l'essai du Crofelemer pour le CID chez les chiens

Crofelemer Jaguar Health Approbation De La FDA Chimiothérapie Canine Traitement De La Diarrhée
BRÈVE

publiée le 08/04/2026 à 14:35, il y a 28 jours 17 heures

Jaguar Health Completes Crofelemer Trial for CID in Dogs

Crofelemer FDA Approval Jaguar Health Dog Chemotherapy Diarrhea Treatment
COMMUNIQUÉ DE PRESSE

publié le 08/04/2026 à 14:30, il y a 28 jours 17 heures

Jaguar Health Completes Effectiveness Trial to Support FDA Approved Crofelemer for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
Jaguar Health, Inc. completes study on crofelemer for cancer therapy-induced diarrhea in dogs. Results expected to complement positive outcomes. Company plans to file effectiveness study by Q2 2026

Crofelemer Jaguar Health Cancer Therapy Diarrhea Dogs
BRÈVE

publiée le 07/04/2026 à 14:35, il y a 29 jours 17 heures

Jaguar Health annonce des résultats financiers mitigés pour 2025

Jaguar Health Résultats Financiers 2025 Appel Du Nasdaq Accord Futur Sur Le Pakistan Médicaments Crofelemer
BRÈVE

publiée le 07/04/2026 à 14:35, il y a 29 jours 17 heures

Jaguar Health Reports Mixed Financial Results for 2025

Jaguar Health Financial Results 2025 Crofelemer Drugs Nasdaq Appeal Future Pak Agreement
COMMUNIQUÉ DE PRESSE

publié le 07/04/2026 à 14:30, il y a 29 jours 17 heures

Jaguar Health Reports 2025 Financials
Jaguar Health, Inc. reports a 5% increase in net revenue in Q4 2025 compared to Q3 2025. Company receives $16M upfront payment from Future Pak for license agreement. Financial results include revenue breakdown and operational expenses

Financial Results Jaguar Health License Agreement Q4 2025 Net Revenue Increase

Les Echos

Publié le 07/05/2026 à 07:43, il y a 34 minutes

ENGIE - Q1 2026 financial information
Publié le 07/05/2026 à 07:43, il y a 34 minutes

ENGIE - Information Financière 1er trimestre 2026
Publié le 06/05/2026 à 18:00, il y a 14 heures 17 minutes

Mise à disposition des documents relatifs à l'AG du 4 juin 2026
Publié le 06/05/2026 à 18:00, il y a 14 heures 17 minutes

Access to information in respect of the General Shareholders’ Meeting to be held on June 4, 2026
Publié le 06/05/2026 à 18:00, il y a 14 heures 17 minutes

Information concerning the total number of voting rights and shares in the share capital as of April 30, 2026

Voir tout LES ECHOS COMFI WIRE

Accesswire

Publié le 07/05/2026 à 05:40, il y a 2 heures 37 minutes

New Horizon Aircraft Ltd. Announces Pricing of $20 Million Offering of Common Shares
Publié le 07/05/2026 à 02:00, il y a 6 heures 17 minutes

Lobe Sciences Ltd. Announces Participation in the D. Boral Capital Global Conference in New York
Publié le 06/05/2026 à 23:30, il y a 8 heures 47 minutes

Stabilis Solutions Announces First Quarter 2026 Results
Publié le 06/05/2026 à 23:05, il y a 9 heures 12 minutes

Zomedica Announces Record First Quarter Revenue of $8.8 Million, Reflecting 35% Annual Growth; and $47.5 Million in Liquidity
Publié le 06/05/2026 à 23:00, il y a 9 heures 17 minutes

Green Bridge Metals Strengthens Technical and Strategic Team as 2026 Work Programs Advance

Voir tout ACCESSWIRE

EQS Group

Publié le 07/05/2026 à 08:05, il y a 12 minutes

Hyundai Mobis Develops Power Electric Systems Ready to All EV Models
Publié le 07/05/2026 à 08:05, il y a 12 minutes

Nota AI Signs AI Optimization Technology Supply and Strategic Partnership Agreement with Mobilint Accelerating Commercialization of On-Device AI on Domestic NPU Infrastructure
Publié le 07/05/2026 à 08:00, il y a 17 minutes

Financial results Q1 2026 – Strong, profitable growth
Publié le 07/05/2026 à 08:00, il y a 17 minutes

AIXTRON supplied Planetary GaN MOCVD Systems to Renesas for High-Volume Manufacturing Expansion
Publié le 07/05/2026 à 08:00, il y a 17 minutes

Pentixapharm Reports First Quarter 2026 Results and Highlights Clinical and Regulatory Momentum